Navigation Links
K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business
Date:8/8/2011

for our current products upon their return to the marketplace, as well as the number of preterm births for which Makena™ may be prescribed and its safety profile and side effects profile and acceptance of the degree of patient access to, and pricing for, Makena™;

(7) the possibility that any period of exclusivity may not be realized, including with respect to Makena™, a designated Orphan Drug;

(8) the satisfaction or waiver of the terms and conditions for the continued ownership of the full U.S. and worldwide rights to Makena™ set forth in the previously disclosed Makena™ acquisition agreement, as amended;

(9) the consent decree between the Company and the FDA and the Company's suspension of the production and shipment and the related nationwide recall affecting all of the other products that it manufactured, as well as the related material adverse effect on its revenue, assets and liquidity and capital resources, as more fully described in Part I, Item -- 1 "Business -- (b)Significant Developments -- Discontinuation of Manufacturing and Distribution; Product Recalls; and the FDA Consent Decree" of the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2011 ("2011 Form 10-K");

(10) the two agreements between the Company and the Office of Inspector General of the U.S. Department of Health and Human Services ("HHS OIG") pertaining to the exclusion of our former chief executive officer from participation in federal healthcare programs and pertaining to the dissolution of our ETHEX subsidiary, in order to resolve the risk of potential exclusion of our Company, as more fully described in Part I, Item 1 -- "Business -- (b)Significant Developments -- Agreements with HHS OIG" of the Company's 2011 Form 10-K;

(11) the plea agreement between the Company and the U.S. Department of Justice and the Company's obligations therewith, as well as the related m
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... declines and extinctions around the world have been ... but new research from the National Institute for ... pathogen, ranavirus, may also contribute. , In ... ranavirus, which causes severe hemorrhage of internal organs ... of wood frogs if they are exposed to ...
(Date:7/9/2014)... flatulence and have a reputation for being highly toxic, but ... now being being found to offer potential health benefits in ... and dementia. A new compound (AP39), designed and made at ... therapies, by targeting delivery of very small amounts of the ... , Scientists in Exeter have already found that the compound ...
(Date:7/9/2014)... the most important organs in the human body. Its ... properly this is its synthesis function and ... this is its detoxification function. Lack of exercise and ... the liver. The resulting diseased cells can lead to ... failure. According to the German Liver Foundation, over five ...
Breaking Medicine News(10 mins):Health News:Study cracks how the brain processes emotions 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... Sports as a,distributor of Muscle Pharm products throughout the US. ... and online,fulfillment. , "Having ... help service many,of our customers who call on a daily ... , For inquires about ...
... President of Preclinical Sciences and Marie Green, Ph.D., as ... CAMBRIDGE, Mass., Dec. 1 Taligen Therapeutics ... the appointment of Jeffrey T. Walsh as chief business ... Christopher Horvath, D.V.M., as vice president of preclinical sciences ...
... Computer Services,Inc. (NYSE: ACS ) re-enters the ... government agencies lower costs and increase service.,With the expiration ... a few,agencies, ACS can now offer its proven business ... As the U.S. faces ...
... generations often shared,wonderful memories of active and healthy grandparents ... years. In the last century, with,life expectancy having ... ages",are much more encumbered by health care concerns, which ... care for themselves. In the recently published,Evercare(R) Study of ...
... include information on the story of one soldier,s family who have ... wound of soldiers returning from Iraq is a traumatic brain injury, ... , ... Denver, CO (PRWEB) December 1, 2008 -- ...
... employers and recruiters to use just one source for all ... jobs posted by different employers across the country. Healthcare employers ... The Exchange simplifies and expedites the hiring process for the ... ...
Cached Medicine News:Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 2Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 3Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 2Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 3Health News:Take Time to Care for the Caregiver 2Health News:LegalView Updates Brain Injury Site with Information on TBI Disabled Soldier's Family 2Health News:LegalView Updates Brain Injury Site with Information on TBI Disabled Soldier's Family 3Health News:HeadHunterHealthExchange.com Launched to Enhance Healthcare Recruitment for Employers and Recruiters 2Health News:HeadHunterHealthExchange.com Launched to Enhance Healthcare Recruitment for Employers and Recruiters 3
Joseph skin hook is a single end-sharp with 2 prong....
Experience great vision, comfort and durability in a quarterly-replacement lens....
A unique lens system featuring Balanced Progressive Technology for optimum vision quality at every distance....
The proven daily wear spherical soft contact lens....
Medicine Products: